Fumonisins in swine: the hidden cost of subclinical exposure

In Brief

• Fumonisins are among the most common mycotoxins in corn-based diets.
• Most exposure in commercial systems is subclinical without obvious signs but with measurable biological and economic impact.
• Fumonisins disrupt sphingolipid metabolism, affecting gut integrity, immune function, liver metabolism, and nutrient utilization.
• Guidance levels help prevent overt toxicity, but performance losses can occur below these levels. 

Introduction

While high fumonisin levels are associated with clinical conditions such as porcine pulmonary edema, most commercial systems experience chronic, low to moderate exposure. Pigs often appear normal, yet underlying biological changes reduce efficiency, increase variability, and impact overall performance.

Why Fumonisins Matter: Mode of Action

Fumonisins disrupt sphingolipid metabolism by inhibiting ceramide synthase, leading to:

• Altered cell membrane integrity
• Increased sphinganine to sphingosine (Sa:So) ratio
• Impaired cellular signaling

These changes affect key systems, particularly the gut, liver, and immune system (Wang et al., 1991; Merrill et al., 2001).

In practical terms: cells become less efficient at absorbing nutrients, maintaining barrier function, and responding to stress, leading to poorer gut health, weaker immunity, and reduced performance.

Growth and Feed Efficiency

Reduced average daily gain and feed efficiency can occur even when feed intake appears normal, increasing days to market and cost per unit of gain (Rotter et al., 1996).

Gut Health and Nutrient Absorption

Disruption of intestinal integrity reduces nutrient uptake and increases susceptibility to enteric challenges (Bracarense et al., 2012).

This includes reduced absorption of amino acids, energy, and fat soluble vitamins A, D, and E.

Immune Function

Fumonisins can influence immune responses, increasing variability in disease outcomes and reducing resilience under stress (Grenier & Oswald, 2011).

Metabolic and Organ Function

Liver stress reduces efficiency in nutrient utilization, including:

• Vitamin A, D, and E metabolism
• Energy metabolism such as lipid metabolism and gluconeogenesis (Grenier & Oswald, 2011; EFSA, 2014)

Interpreting Fumonisin Levels in Practice

In the United States, the FDA provides guidance for fumonisins, including 20 ppm in complete swine diets when corn and corn by-products do not exceed 50% of the ration. These values are intended to prevent overt toxicity and protect animal health and the food supply.

Extension resources, including those from Kansas State University, often describe fumonisin effects based on observable clinical outcomes:

• <20 ppm: no signs
• 50–100 ppm: low feed intake, low growth rate, immunosuppression
• >100 ppm: severe lung lesions, labored breathing, cyanosis, and death

However, these reflect visible outcomes, not full biological impact.

Research shows that cellular and physiological changes occur before clinical signs appear, affecting gut integrity, immune response, and nutrient utilization (Riley et al., 1993; Rotter et al., 1996; Grenier and Oswald, 2011).

What does it mean in practical terms: “no signs” does not mean no impact, subclinical effects can still reduce performance and efficiency.

Why Subclinical Risk Is Often Missed

Fumonisin-related losses are often underestimated because:

• Effects are gradual rather than acute
• Animals appear outwardly normal
• Nutritional programs appear adequate on paper
• Losses show up as variability rather than mortality
• Co-contamination and stress can amplify impact

Fumonisins therefore act as a performance risk multiplier, particularly under real-world production conditions.

Managing Fumonisin Risk

An effective approach includes:

• Monitoring
  Routine feed testing to track exposure.
• Interpretation
  Evaluate total diet, production phase, and health status.
• Targeted Mitigation
  Enzymatic biotransformation provides a targeted option for fumonisin management. FUMzyme® converts fumonisins into hydrolyzed forms with reduced biological activity, helping reduce exposure in the gastrointestinal tract. Feeding trials have demonstrated reductions in fumonisin biomarkers (e.g., SA:SO ratio) and improved biological responses under challenge conditions (Heinl et al., 2010; Masching et al., 2016; Paczosa et al 2025).

Conclusion

Fumonisins are a consistent and often underestimated challenge. Most losses occur under subclinical conditions where pigs appear normal but operate below their potential.

By affecting gut integrity, immune function, liver metabolism, and nutrient utilization, fumonisins create a hidden drag on performance.

• Guidance levels prevent clinical issues
• Performance losses can occur below those levels

Managing fumonisin risk is therefore not only about meeting guidance values, but about protecting consistency, efficiency, and overall productivity.